

2021
2 / 24 (水)

THインタビュー・ピッチ 8:00-9:30 / デモ・商談 9:30-10:30

無料
先着50名



瀬尾 享氏
ファイザー



山下隆也氏
JETRO SF

ボーングローバル・タウンホール13 & フォーラム・ピッチイベント2 北米編

Pitch Presentation by



Coaster
Therapeutics



CREATV
BIO



GI Innovation



KisoJi



Twist
Bioscience



Smarttab



Kang
Healthcare



DIANOMI
Therapeutics



総合司会
森本晴久
アストリア

画期的なバーチャル・ビジネスマッチングを是非体験してみてください

”ショートピッチ”の中
から関係有りそうなスタート
アップに目星をつけ

バーチャル展示ブース
の”デモ・テーブル”で
詳細説明を受け

これは！と思う相手と”商談
スペース”にてプライベートな
対面打ち合せを持つ

アジェンダ

8:00 - 8:30 TOWN HALL 13 Interview : ジェトロSF 山下隆也氏 ◎ズーム上のセッションにて

ジェトロの活動内容のご紹介・オープンイノベーションにおけるベストプラクティスについてのイベント

8:30 - 9:30 北米スタートアップ企業によるプレゼンテーション (Live) ◎ズーム上のセッションにて

北米のスタートアップ企業による5分プレゼンテーション+3月のイベントについてご紹介 (英語)

9:30 - 10:30 バーチャルDEMOテーブル・展示ブース・ラウンジにて 商談 ◎バーチャルラウンジにて

- 個別のスタートアップ企業による詳細事業説明
- スタートアップ企業との個別面談

- バーチャルDemo Table/展示ブースにて
- バーチャルラウンジ(個室エリア)にて

日本にしながら世界のエコシステムと出会える、それがボーングローバル

タウンホール・インタビュー ゲスト

プロフィール



山下隆也
ジェトロサンフランシスコ
事務所長

経済産業省出身。日本のスタートアップの北米展開支援、日本企業の北米でのオープンイノベーションのサポート、西海岸管轄州政府・郡との関係構築を通じた日本企業のビジネス展開支援を実施。昨年6月に今後のイノベーション活動を考えるためのオンラインセミナーを4回シリーズで主催。各回とも、本社とシリコンバレー拠点の実務層約1700名が参加。

フォーラム 発表企業

- ❖ **Coaster Therapeutics** (A provide of a technology to protect oncolytic viruses from immune system clearance)
- ❖ **CREATV BIO** (Liquid Cell Biopsy, a Blood Test for Cancer Diagnosis, Treatment and Drug Development)
- ❖ **GI Innovation** (A provider of a technology to accelerate development of fusion protein for mass production)
- ❖ **KisoJi** (A provider of a next generation antibody technology generating all antibodies to all targets)
- ❖ **Twist Bioscience** (Provider of a DNA Writing on Silicon Chip Platform)
- ❖ **Smarttab** (A Provider of personalized wireless drug delivery platform comprised of ingestible capsule with microprocessor)
- ❖ **Kang Healthcare** (Medical Device for breast cancer detection and infertility)
- ❖ **DIANOMI Therapeutics** (Developer of next generation therapeutics for autoimmune diseases)

BornGlobal TOWN HALL MEETING 13 & FORUM – Pitch Event 2 on North America

Free
First 50 attendants



Toru Seo
Pfizer Inc.



Host
Hal Morimoto
Astoria (US)

Startups Showcased at the FORUM



Takanari
Yamashita
JETRO SF



Coaster
Therapeutics



CREATV
BIO



GI Innovation



KisoJi



Twist
Bioscience



Smarttab



Kang
Healthcare



DIANOMI
Therapeutics

Wed., February 24, 2021 8:00-10:30 (JST) Interview/Pitch Presentations/Demo Tables/Exhibits

Identify a potential
match from short pitch
presentations

Gather more detailed
information at
Virtual Demo Table

Meet one-on-one
with the startups
of your choosing

It is as if you are meeting in-person

Program

8:00 – 8:30 TOWN HALL 13 Interview: Takanari Yamashita, JETRO SF @ZOOM Meeting

Scope of Interview: Preview of JETRO March Events on “Best Practices in Open Innovation Activities”

8:30 – 9:30 Startup Presentations (Live) @ZOOM Meeting

Pitch Presentations by Startups, About Presenters in March

9:30 – 10:30 Virtual Exhibit Booth + Theater + Private Meeting @Virtual Lounge

Live presentations/Pre-recorded Pitches by Startups
One-on-one meeting with Startup Presenters

@Virtual Demo Table/Virtual Exhibit Booth
@Virtual Lounge (Private Room)

TOWN HALL Interview

Guest Speaker

Profile



Takanari (Tak) Yamashita
Chief Executive Director
JETRO SF

Tak Yamashita has experiences in Fukushima restoration, manufacturing and IoT industries, and related fields due to his many years of service since he joined the METI in 1990. He has been the Chief Executive Director of JETRO San Francisco office since November 2019. Before working with JETRO, he served as a Chief Director for the Japanese government’s Nuclear Emergency Response Headquarters, Cabinet Office.

Startups introduced in February FORUM

- ❖ **Coaster Therapeutics** (A provide of a technology to protect oncolytic viruses from immune system clearance)
- ❖ **CREATV BIO** (Liquid Cell Biopsy, a Blood Test for Cancer Diagnosis, Treatment and Drug Development)
- ❖ **GI Innovation** (A provider of a technology to accelerate development of fusion proteiin for mass production)
- ❖ **KisoJi** (A provider of a next generation antibody technology generating all antibodies to all targets)
- ❖ **Twist Bioscience** (Provider of a DNA Writing on Silicon Chip Platform)
- ❖ **Smarttab** (A Provider of personalized wireless drug delivery platform comprised of ingestible capsule with microprocessor)
- ❖ **Kang Healthcare** (Medical Device for breast cancer detection and infertility)
- ❖ **DIANOMI Therapeutics** (Developer of next generation therapeutics for autoimmune diseases)



BornGlobal FORUM - PITCH EVENT

ボーングローバルフォーラム・ピッチイベント

世界のイノベーター、起業家、投資家をつなげるネットワーク

A Trusted Network of Inner Circle Professionals

BornGlobal Virtual Lounge

Pitch Video Theaters, Demo Tables/Exhibit Booths, Virtual Lounge

バーチャルラウンジ
ビデオシアター・展示ブース・DEMOテーブル・商談スペース



Coaster Therapeutics




Coaster Therapeutics

BIOLOGICAL PAYLOAD DELIVERED

Company:

URL:
<http://coastartherapeutics.com>
Founded: 2017
Location: San Diego, CA
Contact: Eddie Chung
Email:
echung@coastartherapeutics.com
Phone: (+1) 858-888-3560




Company Summary

Provides an innovative technology to protect oncolytic viruses from immune system clearance

- Enable oncolytic viruses to be safely delivered to tumor tissues
- Improve the efficacy of virotherapy upon repeated virus administration.

The Problem

Recent studies have shown that oncolytic viruses are coming into prominence for their potential to treat a broad range of cancers and synergistic effect with current immuno-oncology drugs. However, one of **the biggest challenges to oncolytic viral therapy is the virus clearance by the immune system**, especially in repeated doses of the virus, which limits the viral therapy to only intratumoral injection.



Our Solution

Coaster's proprietary ELCV platform can address this issue. **By coating therapeutic viruses with a layer of human cell lipid, we can conceal the virus from immune system clearance.** This will increase the overall efficacy of the treatment and allows us to:

- 1** Reduce the required dose to achieve same therapeutic effect, which can help reduce the cost of the treatment
- 2** Allow intravenous administration of the virus to allow more cancers to be treated with oncolytic viruses



Bare virus	Lipid coated virus

CAMLs Provide Two Approaches to Patient Management

Cancer Associated Macrophage-like Cells in the blood stream
unique to solid cancers that contains tumor proteins and DNA

Assess the tumor

Assess the patient response to the therapy



LifeTracDx™ Liquid Cell Biopsy


Blood Test for Cancer Diagnosis, Treatment, and Drug Development



- Collects circulating cancer associated cells from the tumor site

- Circulating Tumor Cells
- Stromal cells** – giant macrophages with engulfed tumor cells
 - Found in all solid tumors (>20 types)
 - Common in all stages (I-IV)
 - Contain tumor proteins, tumor DNA, and immune markers

Cancer Associated Macrophage-Like Cells (CAMLs)



- CellSieve™** Precision filtration

- 7 μm pores, uniform distribution
- Manufactured by Creatv
- Straightforward & rapid (3 min process)

- LifeTracDx™** Assay

- > 20 peer reviewed publications
- > 15 clinical trials



- Cancer Screening
- Companion Diagnostics
- Prognosis
- Predict Response to therapy
- Identify Recurrence
- Find New Drugs

Comparison of Liquid Biopsies

LifeTracDx™ provides information about the tumor and patient's response to therapy



Utility	LifeTracDx™	CTCs	ctDNA / Methylation	Protein Biomarkers
Solid Tumor Types	★★★★★	Breast, Prostate, Colorectal	★★★★★	★
Stages of Detection	★★★★★ (Stage I-IV)	Stage III-IV	★★★★★	★
Companion Diagnostics	★★★★★	★	★	★
Prediction of Treatment Response	★★★★★	★	★★	★
Early Identification of Recurrence	★★★★★	★	★★★★★	★
Real-Time Monitoring	★★★★★		★	★
Pan Cancer Screening	★★★★★		★★★★★	
Rapid Prognosis	★★★★★	★	★	★

LifeTracDx™ Assay

- Proprietary **CellSieve™** filter


- 7 μm pore diameter
- 180,000 pores in a 9 mm diameter area
- Manufactured by Creatv

- LifeTracDx™** Assay

- Filter 7.5 ml. of whole blood in 3 min
- Removes all red blood cells
- Removes > 99% white blood cells
- Staining the cells

- Collects all cancer associated cells

- CAMLs – in all solid tumors tested
- EMTs (epithelial mesenchymal cells)
- CTCs (circulating tumor cells)




Platform Technology

GI-SMART™ Platform Technology:


- 1) allows to accelerate development of fusion proteins for mass production
- 2) is composed of **SMART-cLego™** & **SMART-Selex™**

➤ **SMART-cLego™**: Fast cloning by Lego-like gene block integration



Enable **high yields** of fusion proteins

➤ **SMART-Selex™**: Unique library-based protein structure




Optimal combination of linkers, hinges, variant Fc for **enhanced affinity and stability**

11


www.gi-innovation.com/en/index.php

Advanced Pipelines

GI-101 is a novel bi-specific CD80/IL2 variant fusion protein, pertaining a superior anti tumor efficacy



GI-301 is a novel IgE-trap for various allergic diseases, pertaining higher and more durable binding to IgE



For contact



12

www.gi-innovation.com/en/index.php



KISOJI ANTIBODY TECHNOLOGIES




KisoMouse

- Multi-species transgenic mouse to generate high resolution single domain antibodies
- Broadest antibody diversity from any animal
- Covers all immune gaps

KisoSeek

- AI / NGS epitope data mining platform
- Allows mapping of millions of individual antibodies to target epitopes
- Machine learning provides prospective search capabilities of all antibodies in library



KisoBody

- Modular design to construct multi-specific antibodies
- Allows multiple mechanisms of action to harness compound biology
- High titers, high purity and simple to manufacture



13

4

KisoJi Biotechnology Inc.

KisoJi is a leading next-generation antibody company generating all antibodies to all targets

Immuno-oncology pipeline of tri-specific antibodies

Research	In Vivo POC	Lead Candidate Selection	IND	Indications
KJ-101			Q4 2021	Small cell lung cancer Other solid tumors Myeloma
KJ-102				AML Solid Tumors
KJ-103				Undisclosed
KJ-104				Cytokine Release Syndrome



www.kisojibiotech.com



Twist DNA Writing on Silicon Platform

Everyone Else

1 Oligo per well



96 Well Plate makes 1 gene



1M Oligos per chip



State of the art commercial infrastructure

- Proprietary software
- Robotics
- Integrated ecommerce platform
- Manufacturing execution system

Up to **10,000x** more scale & throughput

Twist Silicon Platform can make 9,600 genes

We are Building a Diverse Portfolio of Businesses



Drug Discovery

Data Storage

Synthetic Biology

Next-Gen Sequencing

High-value solutions

- Cancer therapeutics
- Autoimmune diseases
- Infectious diseases
- Neuroscience

High-impact tools

- Companion diagnostics
- Precision medicine
- Green energy
- Biomaterials

smarttab

THE FUTURE OF DIGITAL MEDICINE

The SmartTab technology platform is a personalized wireless drug delivery solution comprised of an ingestible capsule with a microprocessor, smart polymer actuator, and active ingredients. Providing novel effective therapies to improve patient outcomes and compliance.



FIRST PATENT ISSUED IN 2017

"Wireless Communications System Integrating Electronics Into Orally Ingestible Products for Controlled Release of Active Ingredients"

2019 PK STUDY CONCLUSION

Via radiofrequency signaling, the SmartTab capsule can successfully administer active ingredients (caffeine) on demand to the target site.



TARGETTAB

SmartTab's wireless capsule designed specifically for targeted delivery of medication when and where you need it most.

Successfully Completed PK Pre-clinical Animal Studies in 2019.



INJECTTAB

SmartTab's wireless capsule for injection of biologics and large molecules. Making injections with needles a thing of the past.

PK Pre-clinical Animal Studies in progress.



MULTITAB

SmartTab's wireless multi-compartment capsule to reside in the stomach for a week and release active ingredients each day.

PK Pre-clinical Animal Studies to begin in 2021.